T 4 levels are determinant of several components of the fibrinolytic system. However, relationships between hypothyroidism and alteration of fibrinolytic capacity are not well established, and published data remain conflicting. As the impact of hypothyroidism on both degradation and synthesis of proteins may vary according to the severity of the disease, we measured fibrinolytic activity across varying states of hypothyroidism. We measured fibrinogen, D-dimers (DDI), ␣ 2 -antiplasmin activity, tissue plasminogen activator antigen (t-PA Ag), plasminogen, plasminogen activator inhibitor antigen (PAI-1 Ag), and factor XII (FXII) of the coagulation. We prospectively included 76 middle-aged female subjects: 25 controls, 24 patients displaying moderate hypothyroidism (TSH, 10 -50 mU/L), and 27 patients with severe hypothyroidism (TSH, Ͼ50 mU/L). Blood pressure, body mass index, smoking habits, total cholesterol as well as high and low density lipoprotein subfractions, triglyceride, fasting glycemia, and insulinemia were recorded.
T HYROID DYSFUNCTION, particularly hypothyroidism, is a common disorder in the general population and occurs more frequently in women. Patients displaying overt hypothyroidism are at high risk for cardiovascular disease (1) (2) (3) (4) . Subsequently, patients with subclinical hypothyroidism [i.e. high TSH levels and normal free T 4 (FT 4 ) levels] were also shown to be at high risk for atherosclerosis and cardiovascular disease (5, 6) . A retrospective study corroborates the strong relationship between low plasma thyroid hormone levels and progression of cardiovascular disease (7) . In contrast to the association of cardiovascular disease with moderate hypothyroidism, a bleeding tendency is described in patients with profound hypothyroidism (8 -10) .
The mechanisms by which low levels of thyroid hormones may lead to atherosclerosis and its complications or, alternatively, to a bleeding tendency remain controversial. Indeed, these hormones have pleiotropic effects on the cardiovascular system. These effects include 1) direct action on myocardium and arteries (3, (11) (12) (13) , 2) qualitative and quantitative modifications of lipoproteins (14) , 3) effect on plasma homocysteine concentration (15) , and 4) modification of circulating coagulation proteins and impaired fibrinolytic activity (8, 10, 16 -19) . We and others have found that plasma levels of fibrinogen (20, 21) , d-dimers (DDI) (22) , and plasminogen activator inhibitor type 1 (PAI-1) (17) (18) (19) 22) were either correlated to plasma levels of T 4 or altered in patients displaying normal to low FT 4 levels or hypothyroidism. However, surprisingly, few studies have analyzed alteration of fibrinolytic activity in patients with hypothyroidism. Furthermore, published data remain controversial, and the different results observed may be explained by the inclusion of patients regardless of the severity of hypothyroidism. Indeed, T 4 has an impact on synthesis and catabolism of proteins, and final modification of serum levels of these proteins may depend on the severity of the disease. Therefore, we undertook the present study to investigate 1) whether hypothyroidism would affect fibrinolytic activity, 2) whether similar abnormalities were observed across varying states of hypothyroidism, and 3) whether a confounding factor(s) may explain alterations in fibrinolytic activity in hypothyroidism.
Subjects and Methods Patients
We prospectively included 51 consecutive female patients with hypothyroidism and 24 controls recruited among patients attending our out-patient clinic for nontoxic goiter or asymptomatic benign nodule. All patients were willing to participate to the study and gave written informed consent. Controls were defined by serum FT 4 and TSH levels within the normal range. Clinical examination included height and weight measurements, and body mass index (BMI) was calculated as weight (kilograms) divided by height (meters) squared. Blood pressure was taken after 10 min in a resting position. A complete medical history, including history of bleeding, was recorded. Patients who presented before the study myocardial infarction or any serious medical disease were excluded. For smoking habits, patients were classified as current smoker or nonsmoker, and cumulative smoking was calculated as packyear. Treatment, including estrogen replacement therapy, received by patients and controls were recorded. None of our patients was taking aspirin on a current basis.
Methods
Blood was collected in the morning between 0800 -0900 h after an overnight fast. Serum levels of FT 4 were measured by immunoluminometric assay (ILMA) by Lumitest FT 4 (Brahms, Germany; normal range, 10 -25 pmol/L) and TSH by ILMA by Lumitest TSH (Brahms; normal range, 0.1-4 mU/L). Thyroid autoantibodies (antibodies to thyroid peroxidase and thyroglobulin) were measured by an enzyme-linked immunosorbent assay (Synelisa, Pharmacia, Germany). Antibody levels were considered negative when they were below 100 IU/mL. Total cholesterol and triglyceride levels were determined on a Kone analyzer by an enzymatic method (BioMérieux, Marcy-l'Etoile, France). High density lipoprotein (HDL) cholesterol was determined by a phosphotungstic acid/MgCl 2 reagent (Roche Molecular Biochemicals, Mannheim, Germany) to precipitate the apolipoprotein B-containing lipoproteins and cholesterol was measured as indicated above. Low density lipoprotein (LDL) cholesterol levels were calculated according to Friedewald's formula. Blood glucose was determined by routine clinical chemistry. A double antibody RIA measured serum insulin levels (AxSYM) with a sensitivity of 1 U/mL with respective intra-and interassay variations of 2.6 -4.9% and 2-2.9%. Insulin resistance was evaluated by the fasting glucose/fasting insulin ratio. For coagulation and fibrinolysis, a venous blood sample (9 vol) was collected into Vacutainer tubes (Becton Dickinson, Mountain View, CA) containing 0.129 mol/L trisodium citrate (1 vol). Platelet-poor plasma was obtained by centrifugation at 3500 ϫ g at 10 C for 20 min. Fibrinogen and FXII measurements were performed immediately. Aliquots of plasma were transferred into plastic tubes without delay and frozen at Ϫ80 C until assays for determination of tissue plasminogen activator antigen (t-PA Ag), plasminogen activator inhibitor 1 antigen (PAI-1 Ag), DDI, and ␣ 2 -antiplasmin. Clottable fibrinogen was assayed by the Clauss method with the commercial reagent Fibromat (BioMérieux). FXII was evaluated using a one-stage clotting assay with aPTT reagent (Organon Teknika Corp., Durham, NC) and specific factor-deficient plasma (STA-Deficient XII, Diagnostica Stago, Asnière sur Seine, France). All of these tests were performed on the automated coagulometer STA (Diagnostica Stago). Normal ranges are 1.8 -3.5 g/L for fibrinogen and 60 -150% for FXII. Measurements of t-PA Ag and PAI-1 Ag used an enzyme-linked immunosorbent assay (Asserachrom tPA and Asserachrom PAI-1 from Diagnostica Stago). According to the manufacturer, normal ranges are 1-12 ng/mL for t-PA Ag and 4 -43 ng/mL for PAI-1 Ag. Determination of functional activity of ␣ 2 -antiplasmin in plasma was made using an amidolytic assay (Berichrom ␣ 2 -antiplasmin, Dade Behring, Marburg, Germany). This assay was performed on a BCT analyzer (Dade Behring). Normal ranges, as determined by the manufacturer, are 80 -100%. DDI measurement was performed by a standard enzyme-linked immunosorbent assay (Asserachrom D-Di ELISA, Diagnostica Stago). Normal values are less than 400 ng/mL.
Statistical analysis
Results are presented as the mean Ϯ sd. We divided patients into two subgroups, which were determined before the study: moderate and profound hypothyroidism defined by serum TSH levels below 50 mU/L and above 50 mU/L, respectively. Results were evaluated by ANOVA and Scheffe's F test for comparison between groups. Relationships between FT 4 and the other biological parameters were assessed by a simple regression analysis. Log transformation of the data was performed when appropriate, as was the case for PAI-1 Ag, t-PA Ag, triglycerides, and DDI. P Ͻ 0.05 was considered significant. FT 4 
Results

Controls and patients: clinical description
Our population included 76 middle-aged female subjects. Twenty-five control subjects had normal TSH and FT 4 levels, 24 presented moderate hypothyroidism (TSH, 10 -50 mU/L), and 27 had severe hypothyroidism (TSH, Ͼ50 mU/L). Among patients with moderate hypothyroidism, 11 presented subclinical hypothyroidism (normal FT 4 levels). Among hypothyroid patients, 38 had chronic Hashimoto thyroiditis, 6 had atrophic thyroiditis, 3 had hypothyroidism secondary to interferon treatment for hepatitis, 2 had hypothyroidism secondary to lithium treatment, one had hypothyroidism secondary to subacute thyroiditis, and one had postpartum thyroiditis. There were no significant differences between groups for mean age, BMI, and estrogen replacement therapy. Smoking habits, cumulative smoking, and mean blood pressure were not different among the 3 subgroups. Clinical parameters are presented according to thyroid status in Table 1 .
Hemostatic and lipid parameters in controls and patients divided into two groups
A nonsignificant decrease in mean fibrinogen levels was observed in patients as the degree of hypothyroidism worsened. Compared with control subjects, patients with moderate hypothyroidism had lower DDI levels, higher ␣ 2 -antiplasmin activities, and higher t-PA and PAI-1 Ag levels, whereas a distinct feature was encountered in those who had severe hypothyroidism (Table 2) . Indeed, in patients with severe hypothyroidism, DDI levels were higher than those in both controls and patients with moderate hypothyroidism; in N, Number of patients; BMI, body mass index; cumulative smoking, pack-year; blood pressure expressed in millimeters of Hg. There were no statistical differences for these parameters, except for TSH, which was significantly higher in moderate hypothyroidism than in controls and significantly higher in severe hypothyroidism than in moderate hypothyroidism.
a P Ͻ 0.0001.
contrast, ␣ 2 -antiplasmin activities and PAI-1 and t-PA Ag levels were lower than those in both controls and patients with moderate hypothyroidism. Exclusion of smokers did not change the results (Table 3) . Similarly, exclusion of women treated with estrogen replacement therapy did not change the differences found among the 3 groups (differences for t-PA Ag were significant only after log transformation; Table 4 ). For DDI, 1 patient in the subgroup of patients with severe hypothyroidism was an outliner with a plasma DDI level of 2001 ng/mL. When this patient was removed from the analysis, differences between groups remained significant (311 Ϯ 187, 284.5 Ϯ 95.9, and 400.6 Ϯ 256 in the control group and in patients with moderate and severe hypothyroidism, respectively; P ϭ 0.038) as did differences between patients with moderate or severe hypothyroidism (P Ͻ 0.05, by Scheffe's F test). Platelet count was Results after exclusion of women taking estrogen replacement therapy are presented as the mean Ϯ SD. Comparison among the three groups was made using ANOVA. DDI, D-Dimers; t-PA Ag, tissue plasminogen activator antigen; PAI-1 Ag, plasminogen activator inhibitor type 1 antigen.
a After log transformation, P ϭ 0.043. not different among the 3 subgroups. Only total cholesterol differed among the groups and LDL cholesterol levels were higher, but the difference failed to reach statistical significance. The results were not different when we included in the analysis the presence or absence of autoimmunity assessed by the measurement of antibodies to thyroid peroxidase and thyroglobulin (data available for 38 patients with hypothyroidism).
PAI-1 levels according to FT 4 quintiles
We divided the overall population according to FT 4 quintiles (mean FT 4 levels were 3.7, 7, 9.8, 12.6, and 16.8 pmol/L in quintiles 1-5, respectively). We observed an increase in plasma levels of PAI-1 in patients in the second, third, and fourth quintiles, whereas patients in the first quintile exhibited significantly lower levels of PAI-1 (Fig. 1) . These patients displayed severe hypothyroidism as indicated by very low mean FT 4 levels.
Correlation coefficients (Table 5)
In the overall study group, a significant positive correlation was found between FT 4 and fibrinogen (r ϭ 0.33), FT 4 and log PAI-1 Ag (r ϭ 0.27), and FT 4 and ␣ 2 -antiplasmin (r ϭ 0.32). A negative correlation was found between FT 4 and log DDI (r ϭ Ϫ0.24). For DDI, when the outliner patient was removed from the analysis, correlation coefficient failed to reach significance. FT 4 was also significantly associated with total and LDL cholesterol and triglycerides. No associations were found between FT 4 and the following characteristics: age, BMI, log t-PA Ag, plasminogen, FXII, HDL cholesterol, fasting glucose, fasting insulin, glucose/insulin ratio, and systolic and diastolic blood pressures.
Discussion
The main finding of our study is that hypothyroid patients display a distinct pattern of alteration of the fibrinolytic system depending on the severity of the disease. Compared with controls, patients with moderate hypothyroidism had lower DDI levels, higher ␣ 2 -antiplasmin activities, and higher t-PA and PAI-1 Ag levels, whereas those who had severe hypothyroidism exhibited higher DDI levels, lower ␣ 2 -antiplasmin activities, and lower t-PA and PAI-1 Ag levels.
This biphasic effect of thyroid hormone deficiency might explain the contradictory results previously found in the literature. Some studies of hypothyroidism found low levels of t-PA and PAI-1 activities (17) and increased fibrinolytic activity (19) , whereas others found the opposite results, i.e. plasma PAI-1 activity increased (16, 18) . However, these studies included a small number of patients and did not compare the effects of severe and moderate hypothyroidism.
We included a carefully selected group of subjects. Male and female subjects may have different patterns of fibrinolytic parameters. Therefore, as hypothyroidism is far more frequent in women, we only included female patients. As we included patients without a prior history of myocardial infarction, we cannot explain our results by a referral bias (i.e. those patients with hypothyroidism and acute cardiovascular event would have been more likely referred to a specialized center).
We analyzed whether differences in fibrinolytic activity could be explained by any of the components of the so-called plurimetabolic syndrome. Indeed, triglyceride and blood glucose levels as well as fasting insulin and BMI were significantly correlated to PAI levels (23, 24) . However, none of these characteristics differed significantly between patients with either moderate or severe hypothyroidism and controls. Our results are in line with the finding that there was no link between thyroid hormones and the insulin resistance syndrome (25) . Smoking is associated with increased prevalence of hypothyroidism (26) and impaired endogenous fibrinolysis (27) . However, we found the same results in nonsmokers. Finally, as aging might affect both thyroid status (28) and fibrinolysis (29) , it is noticeable that our study population involved middle-aged subjects, and mean age did not differ significantly between patients and controls. Taken together, our results strongly suggest that the alteration of the fibrinolytic system found in our patients were only explained by thyroid status.
The finding that patients with severe hypothyroidism display both higher DDI levels and slightly lower fibrinogen levels than controls suggests that these patients present an increased capacity of degradation of normal amount of fibrin. This increased capacity might be explained by decreased levels of PAI-1 Ag and reduced levels of ␣ 2 -antiplasmin. Such modifications may contribute to the bleeding tendency described in these patients. High DDI levels were shown to be a risk factor for cardiovascular disease (30, 31) . Whether this remains true for our population is therefore debatable. It is noticeable that no major increase risk of thrombotic events was described in patients with severe hypothyroidism.
In sharp contrast, the finding of lower DDI levels without significant modification of fibrinogen levels in patients with moderate hypothyroidism suggests a decreased capacity of degradation of normal amount of fibrin. This hypofibrinolytic state might be explained by increased levels of both PAI-1 Ag and ␣ 2 -antiplasmin. In this respect, it is interesting to note that myocardial infarction occurrence in hypothyroid patients was described during the rapid initiation of levothyroxine treatment, a state during which patients have moderate hypothyroidism (2, 32) . This is particularly true for elderly subjects or patients with preexisting ischemic heart disease in whom high t-PA and PAI-1 levels precede acute myocardial infarction (33) (34) (35) . Two recent epidemiological studies support the concept that subclinical hypothyroidism is an independent cardiovascular risk factor (4, 6) . Therefore, accumulating evidence suggests that moderate hypothyroidism should not be regarded as benign.
Binding of plasmin to ␣ 2 -antiplasmin forms inactive complexes. The finding of relatively higher levels of ␣ 2 -antiplasmin in moderate hypothyroidism suggests higher inactivation of plasmin. To our knowledge, there is only one small study of patients with hypothyroidism in which FXII was determined (19) . Our results indicate that FXII levels were not different between patients with and without hypothyroidism. Thus, differences found in DDI or fibrinogen levels cannot be explained by differences in plasma levels of this factor, which has fibrinolytic properties (36, 37) .
The mechanisms by which thyroid hormone status is associated with fibrinolysis alteration remain to be established. The main hypotheses are the following: 1) reduction of catecholamine receptor density in hypothyroidism, leading to an increase in PAI-1 level (38); 2) consequences of atherosclerosis and endothelial dysfunction, a condition associated with reduced release of hemostatic factors (39); 3) direct effect of thyroid hormones on either synthesis or catabolism of proteins; and, finally, 4) indirect effect through autoimmunity. However, although our population is too small to draw any firm conclusion, our results do not suggest that autoimmunity as detected by positive antibodies to thyroglobulin or that thyroid peroxidase is associated with greater abnormalities of fibrinolytic components.
In conclusion, we found a hypofibrinolytic state in patients with moderate hypothyroidism. Our results suggest that the risk of developing thrombosis and ultimately myocardial infarction via high PAI-1 levels may be increased in patients with moderate hypothyroidism, a result in line with recent epidemiological data (4, 6) . These results are of importance because in a large cross-sectional study in which prevalence of hypothyroidism was high (9.5%), 40% of patients were incompletely controlled by T 4 substitution (40) . In contrast, patients with severe hypothyroidism not only have low levels of von Willebrand factor (8, 9) , but also exhibit a reversal toward an activation of the fibrinolytic system. The clinical relevance of higher DDI levels in patients with severe hypothyroidism is debatable. Whether these differences may lead to a somewhat lower risk of myocardial infarction in patients with severe hypothyroidism compared with patients with moderate hypothyroidism remains to be established.
